Amarin Corp Plc - Company Profile
Powered by 
All the sales intelligence you need on Amarin Corp Plc in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Amarin Corp Plc fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Amarin Corp Plc.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Amarin Corp Plc (Amarin) is a pharmaceutical company which develops and commercializes medicines for cardiovascular diseases. The company's lead product, Vascepa (icosapent ethyl) is a single-molecule prescription capsule used as an adjunct to diet for the reduction of triglyceride levels in adult patients with severe hypertriglyceridemia and high triglyceride levels or mixed dyslipidemia and cardiovascular risk. Amarin is also evaluating Vascepa as an add-on therapy to reduce major cardiovascular events in an at-risk patient population on statin therapy. The company markets the product in the US through wholesalers and specialty pharmacy providers. The company has operations in Ireland, the US, Germany, Switzerland, the Uk, Italy, France, and Israel. Amarin is headquartered at Dublin, Ireland.
Headquarters
Ireland
Address
8th Floor, One Central Plaza, 36 Dame Street, Dublin, D02K7K5
Website
www.amarincorp.com
Telephone
353 1 6699020
No of Employees
80
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
AMRN (NASD)
Revenue (2025)
$213.6M
-6.5%
(2025 vs 2024)
EPS
XYZ
Net Income (2025)
XYZ
52.8%
(2025 vs 2024)
Market Cap*
$341.1M
Net Profit Margin (2025)
XYZ
49.5%
(2025 vs 2024)
* As of and is in US$
Amarin Corp Plc premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Vascepa Capsules | Vascepa |
| Pipeline Programs: | Reduce-IT |
| Vascepa: | |
| XYZ | |
| XYZ | |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2025 | Contracts/Agreements | In June 2025, the company entered into a long-term license and supply agreement with Recordati SpA to commercialize VAZKEPA (icosapent ethyl) in 59 countries, primarily in Europe. |
| 2025 | Plans/Strategy | In March, the company announced its intent to effect a ratio change on its American Depositary Shares. |
| 2024 | New Products/Services | In April, the company introduced Reduce-It analyses show and Vascepa/Vazkepa(Icosapent Ethyl), it will give benefit in high-risk cardiovascular disease patient subgroups. |
Competitor Comparison
| Key Parameters | Amarin Corp Plc | Zydus Lifesciences Ltd | OneSource Specialty Pharma Ltd | Apotex Inc | Ascent Pharmaceuticals Inc |
|---|---|---|---|---|---|
| Headquarters | Ireland | India | India | Canada | United States of America |
| City | Dublin | Ahmedabad | Bengaluru | Toronto | Central Islip |
| State/Province | Dublin | Gujarat | Karnataka | Ontario | New York |
| No. of Employees | 80 | 23,283 | 1,412 | 6,000 | - |
| Entity Type | Public | Public | Public | Private | Private |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Aaron D. Berg | President; Chief Executive Officer; Director | Executive Board | 2024 | 63 |
| Peter L. Fishman | Chief Financial Officer; Senior Vice President | Senior Management | 2024 | 42 |
| Jonathan N. Provoost | Executive Vice President; Chief Compliance Officer; Chief Legal Officer; Secretary | Senior Management | 2023 | 56 |
| Steven B. Ketchum, Ph.D. | Chief Scientific Officer; President - Research and Development; Executive Vice President | Senior Management | 2016 | 61 |
| David Keenan, PhD | Chief Operating Officer; Executive Vice President | Senior Management | 2025 | 59 |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer